Evidence map›Paper›PMID 38545345›Full record

ArticleFrontiers in cardiovascular medicine2024

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany.

Philipp Hillmeister, Kangbo Li, Mengjun Dai, Mesud Sacirovic, Nikolaos Pagonas, Oliver Ritter, Peter Bramlage, Anja Bondke Persson, Ivo Buschmann, Claudia Zemmrich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Philipp HillmeisterDepartment for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Kangbo LiDepartment for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Mengjun DaiDepartment for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Mesud SacirovicDepartment for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Nikolaos PagonasFaculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Oliver RitterFaculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Peter BramlageInstitute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
Anja Bondke PerssonCharité-Universitätsmedizin Berlin, Berlin, Germany.
Ivo Buschmann *Department for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Claudia Zemmrich *Department for Angiology, Center for Internal Medicine I, Deutsches Angiologie Zentrum (DAZB), University Clinic Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Brandenburg/Havel, Germany.
Medizinische Hochschule Brandenburg Theodor Fontane · DEIPPMed (Germany) · DEKlinikum Brandenburg · DEBrandenburg University of Technology Cottbus-Senftenberg · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. In addition, data from patients with atherosclerotic cardiovascular disease (ASCVD) in diverse regional backgrounds, including the understudied Brandenburg cohort, and various healthcare statuses remain insufficient. Methods: In this WalkByLab study, Lp(a) levels were monitored in a non-metropolitan cohort ( Results: Brandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.2% vs. 14.8%, Conclusions: Our study highlights the significance of elevated Lp(a) levels in Brandenburg cardiovascular patients and identifies them as an independent risk factor for ASCVD, which has implications for addressing cardiovascular health of non-metropolitan populations.

Indexed as

atherosclerotic cardiovascular diseaseGermanyLipoprotein (a)non-metropolitan arearisk factor

Identifiers

PMID38545345
PMCPMC10967658
OpenAlexW4392559327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.